JP2005502675A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502675A5
JP2005502675A5 JP2003524562A JP2003524562A JP2005502675A5 JP 2005502675 A5 JP2005502675 A5 JP 2005502675A5 JP 2003524562 A JP2003524562 A JP 2003524562A JP 2003524562 A JP2003524562 A JP 2003524562A JP 2005502675 A5 JP2005502675 A5 JP 2005502675A5
Authority
JP
Japan
Prior art keywords
mometasone furoate
formoterol fumarate
suspension formulation
metered dose
dose inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003524562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/027336 external-priority patent/WO2003020253A2/en
Publication of JP2005502675A publication Critical patent/JP2005502675A/ja
Publication of JP2005502675A5 publication Critical patent/JP2005502675A5/ja
Pending legal-status Critical Current

Links

JP2003524562A 2001-08-28 2002-08-27 喘息治療用の製薬組成物 Pending JP2005502675A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
PCT/US2002/027336 WO2003020253A2 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009126933A Division JP2009185075A (ja) 2001-08-28 2009-05-26 喘息治療用の製薬組成物
JP2010036706A Division JP5170789B2 (ja) 2001-08-28 2010-02-22 喘息治療用の製薬組成物

Publications (2)

Publication Number Publication Date
JP2005502675A JP2005502675A (ja) 2005-01-27
JP2005502675A5 true JP2005502675A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=23224164

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003524562A Pending JP2005502675A (ja) 2001-08-28 2002-08-27 喘息治療用の製薬組成物
JP2009126933A Pending JP2009185075A (ja) 2001-08-28 2009-05-26 喘息治療用の製薬組成物
JP2010036706A Expired - Fee Related JP5170789B2 (ja) 2001-08-28 2010-02-22 喘息治療用の製薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009126933A Pending JP2009185075A (ja) 2001-08-28 2009-05-26 喘息治療用の製薬組成物
JP2010036706A Expired - Fee Related JP5170789B2 (ja) 2001-08-28 2010-02-22 喘息治療用の製薬組成物

Country Status (26)

Country Link
US (3) US20030114428A1 (cg-RX-API-DMAC7.html)
EP (3) EP1420759B1 (cg-RX-API-DMAC7.html)
JP (3) JP2005502675A (cg-RX-API-DMAC7.html)
KR (1) KR100970531B1 (cg-RX-API-DMAC7.html)
CN (2) CN1649568B (cg-RX-API-DMAC7.html)
AR (1) AR036358A1 (cg-RX-API-DMAC7.html)
AT (2) ATE430555T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002313828B2 (cg-RX-API-DMAC7.html)
BR (1) BR0212089A (cg-RX-API-DMAC7.html)
CA (1) CA2457926A1 (cg-RX-API-DMAC7.html)
CO (1) CO5560551A2 (cg-RX-API-DMAC7.html)
CY (2) CY1109212T1 (cg-RX-API-DMAC7.html)
DE (2) DE60239648D1 (cg-RX-API-DMAC7.html)
DK (2) DK2092935T3 (cg-RX-API-DMAC7.html)
ES (3) ES2389480T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0401514A3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001875A (cg-RX-API-DMAC7.html)
NO (1) NO20041277L (cg-RX-API-DMAC7.html)
NZ (1) NZ530987A (cg-RX-API-DMAC7.html)
PE (1) PE20030390A1 (cg-RX-API-DMAC7.html)
PL (1) PL209640B1 (cg-RX-API-DMAC7.html)
PT (2) PT1420759E (cg-RX-API-DMAC7.html)
SI (2) SI2092935T1 (cg-RX-API-DMAC7.html)
TW (1) TWI324934B (cg-RX-API-DMAC7.html)
WO (1) WO2003020253A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401419B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
ES2292713T3 (es) * 2001-03-30 2008-03-16 Jagotec Ag Formulaciones medicinales en aerosol.
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング コーポレイション 薬学的組成物
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
DE60336602D1 (de) * 2002-08-27 2011-05-12 Schering Corp Verfahren zur Herstellung von Formulierungen für Inhaliergeräte mit abgemessener Dosis
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
WO2005041931A2 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP2201936B1 (en) * 2004-01-21 2013-06-19 Merck Sharp & Dohme Corp. Method of treating acute rhinosinusitis
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
ES2317306T3 (es) * 2004-10-12 2009-04-16 Generics (Uk) Limited Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol.
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
US20070203104A1 (en) * 2006-02-09 2007-08-30 Chaudhry Saeed M Pharmaceutical Formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
AU2007346134A1 (en) * 2007-02-09 2008-08-14 Merck Sharp & Dohme Corp. Stable pharmaceutical drug aerosols
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
WO2009089422A2 (en) * 2008-01-10 2009-07-16 Schering Corporation Inhalation drug products, systems and uses
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR20170070274A (ko) * 2009-05-29 2017-06-21 펄 테라퓨틱스 인코포레이티드 지속형 무스카린 안타고니스트 및 지속형 b₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
JP5678088B2 (ja) * 2009-12-07 2015-02-25 ラプター セラピューティックス インコーポレイテッドRaptor Therapeutics Inc. 4−メチルピラゾール製剤
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
PL2765994T3 (pl) * 2011-10-11 2019-09-30 Chiesi Farmaceutici S.P.A. Krystaliczne mikrocząstki beta-agonisty pokryte kwasem tłuszczowym
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス,インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
MX379196B (es) 2014-05-07 2025-03-10 Boehringer Ingelheim Int Nebulizador.
EP4235142A3 (en) 2014-06-30 2023-11-22 Proveris Scientific Corporation Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
CA3016890A1 (en) 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
US20210338626A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
EP4228725A4 (en) 2020-10-15 2024-11-06 Proveris Scientific Corporation SYSTEMS AND METHODS FOR INHALATOR TESTING

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
ZA924164B (en) * 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
HUT77775A (hu) * 1994-12-22 1998-08-28 Astra Aktiebolag Aeroszolformák
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
CO4900027A1 (es) * 1996-08-29 2000-03-27 Schering Corp Formulaciones en aerosol de furoato de mometasona sin cloro- fluorocarburos .
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
JP3840515B2 (ja) * 1998-11-26 2006-11-01 ブリタニア・ファーマスーティカルズ・リミテッド 界面活性リン脂質を含む抗喘息の組合せ
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
KR20020070346A (ko) * 2000-01-20 2002-09-05 바실리어 파마슈티카 아게 비강 투여 가능 고리형 펩티드 조성물
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
WO2002011711A2 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Similar Documents

Publication Publication Date Title
JP2005502675A5 (cg-RX-API-DMAC7.html)
JP5170789B2 (ja) 喘息治療用の製薬組成物
US5934273A (en) System for dispensing pharmaceutically active compounds
AU2006278571B2 (en) Compositions exhibiting improved flowability
TW475904B (en) Pharmaceutical composition for administration by inhalation and the preparation thereof
US6250300B1 (en) System for dispensing pharmaceutically active compounds
EP2309978B1 (en) Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
CZ20013185A3 (cs) Farmaceutický prostředek
JPS63502895A (ja) 新規な吸入用製薬組成物
EP1296663A2 (en) Highly efficient delivery of a large therapeutic mass aerosol
Yang et al. Drug delivery performance of the mometasone furoate dry powder inhaler
JP4348179B2 (ja) 安定な粉末吸入投与組成物
CN116615201A (zh) 丙酸氟替卡松和硫酸沙丁胺醇的可吸入制剂
CN102458372A (zh) 适用在干粉吸入器中的聚结物制剂
JP2006312649A (ja) 薬学的組成物
Vanderbist et al. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent
JP2025526811A (ja) 吸入可能なエピネフリン製剤
CA2575957C (en) Process for preparing a medicament
CN116077471A (zh) 一种供吸入用的粉雾剂组合物及其制备方法和应用
JP5345605B2 (ja) 乾燥粉末吸入組成物の製造方法
WO2022045995A1 (en) A process for the preparation of dry powder compositions for inhalation
WO2019098969A2 (en) Dry powder compositions for inhalation
TWI383807B (zh) 醫學氣霧配方
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法
WO2023128918A1 (en) A process including a feeding gas system for preparing dry powder inhalation compositions